Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol

Redman, Mary W.; Papadimitrakopoulou, Vassiliki A.; Minichiello, Katherine; Hirsch, Fred R.; Mack, Philip C.; Schwartz, Lawrence H.; Vokes, Everett E.; Ramalingam, Suresh S.; Leighl, Natasha B.; Bradley, J.D.; Miao, Jieling; Moon, James; Highleyman, Louise; Miwa, Crystal; LeBlanc, Michael; Malik, Shakun; Miller, Vincent A.; Sigal, Ellen V.; Adam, Stacey J.; Wholley, David; Sigman, Caroline C.; Smolich, Beverly D.; Blanke, Charles D.; Kelly, Karen; Gandara, David R.; Herbst, Roy S.

doi:10.1016/s1470-2045(20)30475-7

Cited by 88 publications

(67 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As the c-MET expression is lower in corresponding normal tissues, such tumours are an ideal target for antibody-based biological therapy (22)(23)(24). In addition, c-MET in cancer cells is highly sensitive to antibody-induced internalisation, and the high efficiency of cytotoxic payloads to kill tumour cells requires antibody internalisation; therefore, c-MET therapy has inherent potential as a clinical anti-cancer option (25,26).…”

Section: Discussionmentioning

confidence: 99%

A Novel c-MET-Targeting Antibody-Drug Conjugate for Pancreatic Cancer

et al. 2021

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-associated death in the United States and has a 5-year survival rate of <4%. Although much effort has been invested in the research and development of pancreatic cancer drugs over the past 30 years, due to the lack of effective targetable carcinogenic drivers, no new targeted therapies that can improve patient prognosis have been approved for clinical use. SHR-A1403 is a new c-mesenchymal-epithelial transition factor (c-MET) antibody-drug conjugate that can be used for the targeted treatment of PDAC with high c-MET expression. This study reports for the first time the application prospects of SHR-A1403 in preclinical models of PDAC. SHR-A1403 significantly inhibited the proliferation, migration, and invasion of pancreatic cancer cells and induced cell cycle arrest and apoptosis. These changes were caused by inhibition of intracellular cholesterol biosynthesis by SHR-A1403. Therefore, targeting c-MET through SHR-A1403 showed strong preclinical anti-tumour efficacy in pancreatic cancer. Our work suggests the potential application of c-MET-targeted antibody-drug conjugate treatment for PDAC in clinical practise.

show abstract

Section: Discussionmentioning

confidence: 99%

A Novel c-MET-Targeting Antibody-Drug Conjugate for Pancreatic Cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…We had included also patients with 0 PD-L1 expression which benefited from the combination intratumoral treatment with their performance status improved along with their disease indifferent of an endobronchial or parenchymal lesion. This is known from the first studies of immunotherapy and it is explained with unknown mechanisms of immunoitherapy [42]. Patients with multiple metastatic site and increased tumor burden did not benefit from the combo intratumoral as these patients need systemic drug release.…”

Section: Discussionmentioning

confidence: 99%

Intratumoral Treatment with Chemotherapy and Immunotherapy for NSCLC with EBUS-TBNA 19G

Hohenforst-Schmidt¹,

Huang²,

Zhou³

et al. 2021

J. Cancer

View full text Add to dashboard Cite

Introduction: Immunotherapy is being used for the past five years either as first line or second line treatment with great results. Chemotherapy and radiotherapy have been also used as combination to immunotherapy to further enhance this type of treatment. Intratumoral treatment has been previously proposed as a treatment option for certain non-small cell lung cancer patients. Patients and Methods: We recruited in total seventy four patients with non-small cell lung cancer in their second line treatment who received only chemotherapy in their first line treatment with programmed death-ligand-1 ≤ 50. Only adenocarcinoma or squamous cell carcinoma, and all negative for epidermal growth factor receptor, anaplastic lymphoma kinase, proto-oncogene tyrosine-protein kinase-1 and proto-oncogene B-Raf. Data were first examined with descriptive statistics choosing frequencies for categorical variables and histograms for the continuous ones. Twenty five received only intravenous immunotherapy and forty-nine intravenous cisplatin with immunotherapy. Data were first examined with descriptive statistics choosing frequencies for categorical variables and histograms for the continuous ones.

show abstract

“…Targeted therapy has signi cantly improved the outcome for patients with lung cancer in the last decade [32]. For example, EGFR is a major driver of NSCLC tumorigenesis [33], and tumour growth can be inhibited by treating lung tumours expressing somatic mutations of the EGFR gene with TKIs.…”

Section: Discussionmentioning

confidence: 99%

99mTc-Galacto-RGD2 Integrin αvβ3 Targeted Imaging as a Surrogate for Molecular Phenotyping in Lung Cancer: Prospective Study in the Real World

Fu¹,

Yan²,

Fu³

et al. 2021

Preprint

View full text Add to dashboard Cite

Purpose: Epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) are beneficial in patients with lung cancer. We explored the clinical value of 99mTc-Galacto-RGD2 single-photon emission computed tomography (SPECT/CT) in patients with lung cancer, Integrin αvβ3 expression, and neovascularization in lung cancer subtypes was also addressed. Methods: A total of 185 patients with lung cancer and 25 patients with benign lung diseases were enrolled in this prostective study from January 2013 to December 2016. All patients underwent 99mTc-Galacto-RGD2 imaging. The region of interest was drawn around each primary lesion, and tumour uptake of 99mTc-Galacto-RGD2 was measured as the tumour/normal tissue ratio（T/N）. The diagnostic efficacy was evaluated by receiver operating characteristic curve analysis. Tumour tissues were obtained from 66 patients with malignant diseases and seven with benign disease. Tumour expression levels of αvβ3, CD31, Ki-67, and CXCR4 were analysed to determine their value for phenotyping and metastasis potential evaluation. Results: The lung cancer patients included 22 cases of small cell lung cancer (SCLC), 48 squamous cell carcinoma (LSC), 97 adenocarcinoma (LAC), and 18 other types of lung cancer. The sensitivity, specificity, and accuracy of 99mTc-Galacto-RGD2 SPECT/CT using a cut-off value of 2.5 were 91.89 %, 48.0 %, and 86.67 %, respectively. Integrin αvβ3 expression was higher in non-SCLC compared with SCLC, while LSC showed denser neovascularization and higher integrin αvβ3 expression. Integrin αvβ3 expression levels were significantly higher in advanced (Ⅲ, Ⅳ) than early stages (Ⅰ, Ⅱ). However, there was no significant correlation between tumour uptake and αvβ3 expression. Conclusion: 99mTc-Galacto-RGD2 SPECT/CT has high sensitivity but limited specificity for detecting primary lung cancer. RGD imaging may help evaluate the biological behaviour and phenotyping, and thus aid management in lung cancer.

show abstract

Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol

Cited by 88 publications

References 27 publications

A Novel c-MET-Targeting Antibody-Drug Conjugate for Pancreatic Cancer

A Novel c-MET-Targeting Antibody-Drug Conjugate for Pancreatic Cancer

Intratumoral Treatment with Chemotherapy and Immunotherapy for NSCLC with EBUS-TBNA 19G

99mTc-Galacto-RGD2 Integrin αvβ3 Targeted Imaging as a Surrogate for Molecular Phenotyping in Lung Cancer: Prospective Study in the Real World

Contact Info

Product

Resources

About